| Prev Close | 43.71 |
| Open | 43.56 |
| Day Low/High | 43.49 / 43.77 |
| 52 Wk Low/High | 30.89 / 57.41 |
| Volume | 530.57K |
| Avg Volume | 2.32M |
| Exchange | NYSE |
| Shares Outstanding | 2.55B |
| Market Cap | 110.08B |
| EPS | 2.00 |
| Div & Yield | 1.33 (3.10%) |
Latest News
Nevada Senate Passes Bill to Force Diabetes Drug Manufacturers to Disclose Pricing Practices
The legislation would also force companies to announce planned price hikes.
Dow Holds Lower After House Passes Health Care Vote, Crude Falls
Stocks move mostly lower on Thursday after the House passes a bill to repeal and replace the Affordable Care Act.
Ratings Changes Today
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ANH, DVN, EXEL, FMC, FSI, GLT, MEOH, MJCO, MOH, NVO, RPXC, TECH, WU, WWE Downgrades: CIGI, IPHI, QUOT Initiations: None Read on to get TheStreet Quant Ratings' detailed report:
Novo Nordisk Launches Xultophy® 100/3.6 (insulin Degludec And Liraglutide Injection) In The United States
- New combination treatment option for adults with type 2 diabetes now available in pharmacies
5 Things You Must Know Before the Market Opens Wednesday
U.S. stock futures decline and European shares trade lower following disappointing earnings from Apple and as Wall Street looks to Wednesday's announcement from the Federal Reserve on interest rates.
Novo Nordisk Hits 2017 High After Q1 Profit Beat, Full-Year Guidance Boost
Novo Nordisk shares surged to a year-to-date high Wednesday after the world's biggest maker of insulin posted stronger-than-expected first quarter earnings and boosted its full-year outlook.
European Stocks Slump, Tech Sector Drifts After Apple's iPhone Miss Hits Suppliers
European stocks drifted lower as investors stepped back from a global market rally after disappointing earnings from Apple and weaker U.S. car sales put investors in a cautious mood.
Global Financial News: Apple Takes the Steam Out of the Global Equity Rally
European stocks slip as Apple earnings take the steam out of the global equity rally.
TherapeuticsMD Hormone Pill Faces Looming FDA Rejection and a Hostile Commercial Market
Postmenopausal women already have a broad menu of locally administered estrogen therapy products to treat vulvar and vaginal atrophy.
What to Expect From European Pharmaceuticals' First Quarter Results
New drug launches and late stage trials will be under the microscope as eight European pharmaceuticals companies report Q1 earnings starting next week.
Novo Nordisk Invites The Community To Unmask Everyday Heroes In Recognition Of World Hemophilia Day
#HemoHero stories to illustrate diverse experiences and inspiring acts of people affected by hemophilia
Keller Rohrback L.L.P. Filed Suit Against The Nation's Three Largest Pharmacy Benefit Managers And The Three Major Insulin Manufacturers, Who Produce The Well-known And Widely-prescribed Analog Insulins. (Photo: Business Wire)
Attorney Advertising. On March 17, 2017, the nationally recognized class-action law firm of Keller Rohrback L.
Delta, Barracuda Networks, STMicroelectronics: 'Mad Money' Lightning Round
Jim Cramer is bullish on Delta, Barracuda Networks, STMicroelectronics, UnitedHealth Group.
Deregulation and Energy Policy Can Fuel Markets: Cramer's 'Mad Money' Recap (Friday 3/17/17)
This week the markets fell back on earnings -- like Adobe -- and remained afloat, says Jim Cramer.
SHAREHOLDER ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit Against Novo Nordisk A/S And Encourages Investors With Losses To Contact The Firm
Goldberg Law PC, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Novo Nordisk A/S (" Novo" or the "Company") (NYSE: NVO).
NOVO NORDISK 72 HOUR DEADLINE ALERT: APPROXIMATELY 72 HOURS REMAIN; FORMER LOUISIANA ATTORNEY GENERAL AND KAHN SWICK & FOTI, LLC REMIND INVESTORS Of Deadline In Class Action Lawsuit Against Novo Nordisk A/S - (NVO)
Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C.
Egalet Makes Friday's Biotech Mailbag
Why the name is sagging, and what it will take to spur the sector higher.
